Lumenis taps ‘This Is Us’ star Mandy Moore for first dry eye DTC campaignnews2022-02-11T14:37:46+00:00February 11th, 2022|Fierce Pharma|
Ipsen telegraphs $400M deal for consumer healthcare splitnews2022-02-11T14:18:05+00:00February 11th, 2022|Fierce Pharma|
Lilly back in COVID-19 antibody game with $720 million deal with U.S. for omicron-busting hopefulnews2022-02-11T14:17:24+00:00February 11th, 2022|Fierce Pharma|
Fierce Pharma Asia—Lilly, Innovent’s PD-1 saga; Biogen, Eisai’s Aduhelm rebuttal; Surprise FDA foreign inspections?news2022-02-11T11:55:23+00:00February 11th, 2022|Fierce Pharma|
AbbVie runs first Qulipta TV ad spots as it focuses on what you ‘can control inside’news2022-02-11T11:27:02+00:00February 11th, 2022|Fierce Pharma|
Eli Lilly talks up ‘long-term’ game plan for tirzepatide launch, but don’t expect major sales early onnews2022-02-11T09:11:22+00:00February 11th, 2022|Fierce Pharma|
Thumbs down on Lilly, Innovent China trial for lung cancer drug Tyvyt, says FDA AdCommnews2022-02-10T20:54:31+00:00February 10th, 2022|Fierce Pharma|
Biogen, Eisai strike back against CMS’ stifling Aduhelm coverage proposalnews2022-02-10T18:10:56+00:00February 10th, 2022|Fierce Pharma|
Eli Lilly promises 40% discount for Innovent’s PD-1 in last-ditch bid to shift FDA review to drug pricingnews2022-02-10T16:32:52+00:00February 10th, 2022|Fierce Pharma|
FDA nominee Califf pledges to enforce accelerated approval mandates as he jockeys for Senate supportnews2022-02-10T16:02:48+00:00February 10th, 2022|Fierce Pharma|
